Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Comera Life Sciences Holdings, Inc. (CMRA)

1.37   -0.04 (-2.84%) 01-27 15:59
Open: 1.42 Pre. Close: 1.41
High: 1.52 Low: 1.31
Volume: 237,880 Market Cap: 31(M)

Technical analysis

as of: 2023-01-27 4:43:26 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 2.08     One year: 2.53
Support: Support1: 1.16    Support2: 0.97
Resistance: Resistance1: 1.78    Resistance2: 2.17
Pivot: 1.5
Moving Average: MA(5): 1.38     MA(20): 1.44
MA(100): 1.58     MA(250): 4.55
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 21.3     %D(3): 21.5
RSI: RSI(14): 47.3
52-week: High: 15.3  Low: 1.11
Average Vol(K): 3-Month: 64 (K)  10-Days: 73 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CMRA ] has closed above bottom band by 25.8%. Bollinger Bands are 34.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.52 - 1.53 1.53 - 1.54
Low: 1.29 - 1.3 1.3 - 1.31
Close: 1.36 - 1.37 1.37 - 1.38

Company Description

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Headline News

Wed, 11 Jan 2023
5 ways NOAA supported climate science and solutions in 2022 - National Oceanic and Atmospheric Administration

Mon, 09 Jan 2023
5 hot insider trades: Travelzoo, CarMax By -

Wed, 04 Jan 2023
Comera Life Sciences Closes $3.6 Million Private Placement Priced At-the-Market under Nasdaq Rules - Yahoo Finance

Wed, 28 Dec 2022
3D Motorsports Named Dunlop Race Tire Supplier For CMRA Events -

Wed, 07 Dec 2022
Climate Mapping for Resilience and Adaptation (CMRA) Portal - Government Technology

Wed, 05 Oct 2022
CMRA: Sneed Wins Formula One Race At Hallett -

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 0 (M)
% Held by Insiders 7.24e+006 (%)
% Held by Institutions 50.2 (%)
Shares Short 605 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -9.27e+006
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -2
Return on Assets (ttm) 322.4
Return on Equity (ttm) 0
Qtrly Rev. Growth 403160
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow -8 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 172990
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.